Roche says divarasib cut risk of death 44% in lung cancer trial

ZURICH, Oct 25 (Reuters) Swiss drugmaker Roche said on Sunday its experimental lung cancer drug divarasib reduced the ​risk of death by 44% ‌compared with existing treatments in a phase III study. • Roche said patients with previously treated KRAS G12C-mutated non-small cell lung cancer who received ‌divarasib ​had median overall survival ⁠of nearly 18 months, ⁠compared with 12 months for those treated with sotorasib or adagrasib • Divarasib also lowered the risk of disease progression ​or death by 42%, with median progression-free survival of 9.8 months against ⁠5.7 months in the ⁠control group • The Phase III ​Krascendo 1 trial involved 338 patients and ​compared divarasib with the two approved ‌KRAS G12C inhibitors • The objective response rate was 58% for divarasib, versus 32% for sotorasib or adagrasib • No new safety ⁠findings were observed. Some 4.8% of patients on divarasib stopped treatment because of treatment-related adverse ⁠events, versus ‌11.7% in the control group • ⁠R